SPOTLIGHT -
EP. 1: TRIBE Trial: First-Line Treatment of mCRC
EP. 2: PRIME Trial: RAS Mutations in Metastatic Colorectal Cancer
EP. 3: EPOC Studies: Preoperative Treatments in CRC
EP. 4: FIRE-3 Study: Cetuximab Versus Bevacizumab in mCRC
EP. 5: Predictive Value of RAS Mutations in mCRC
EP. 6: Case Study: Borderline Resectable mCRC
EP. 7: Maintenance Therapy in Metastatic Colorectal Cancer
EP. 8: Antiangiogenic Therapy in Metastatic Colorectal Cancer
EP. 9: Second-Line and Salvage Treatment of mCRC
EP. 10: Novel Therapies in Development for mCRC
EP. 11: Personalized Medicine in Colorectal Cancer
Up-Front Osimertinib Provides Comparable OS, Improved Brain PFS Vs Sequential Gefitinib/Osimertinib in EGFR+ NSCLC
Dr Nasioudis on the Use of NGS to Identify the Molecular Profile of Endometroid Ovarian Cancer
Dr Buckingham on the Use of Patient-reported Outcomes to Predict Frailty in Patients With Ovarian Cancer
Dr Slomovitz on the Investigation of Letrozole Plus Ribociclib in Low-Grade Serous Ovarian Carcinoma
